首页> 外文OA文献 >Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts
【2h】

Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts

机译:使用分级总淋巴照射对成年小鼠诱导的特定组织移植耐受性:同种异体骨髓和皮肤移植物的长期存活

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BALB/c mice were treated with fractionated high dose (3,400 rads) total lymphoid irradiation (TLI), and given semiallogeneic (BALB/c x C57BL/Ka) or allogeneic (C57BL/Ka) bone marrow and/or skin allografts. TLI alone prolonged the mean survival time (m.s.t.) of C57BL/Ka skin grafts to 49.1 days (control, 10.7 days). Shielding of the thymus during TLI produced only a slight increase in graft survival (m.s.t., 19 days). TLI combined with splenectomy was no more effective than TLI alone. Infusion of 10(7) semiallogeneic or allogeneic bone marrow cells after TLI produced stable chimeras in 7/8 and 8/15 recipients, respectively. Chimeras were specifically tolerant to donor tissues, since C57BL/Ka skin grafts were accepted for more than 250 days, but third-party (C3H/He) skin grafts were rejected rapidly. In addition, chimeric lymphocytes responded to C3H/He and C3H. Q but not to C57BL/Ka cells in the one-way mixed leukocyte reactions. BALB/c C57BL/Ka chimeras showed no clinical evidence of graft vs. host disease. These findings may have application of clinical organ transplantation, since (a) the recipient treatment (TLI) has already been shown to be safe in humans, (b) donors and recipients can be completely allogeneic, and (c) bone marrow and skin graft survival was permanent (greater than 250 days).
机译:用分次高剂量(3,400 rads)总淋巴样照射(TLI)治疗BALB / c小鼠,并给予半同种异体(BALB / c x C57BL / Ka)或同种异体(C57BL / Ka)骨髓和/或皮肤同种异体移植。单独使用TLI可将C57BL / Ka皮肤移植物的平均存活时间(m.s.t.)延长至49.1天(对照组,10.7天)。在TLI期间对胸腺进行屏蔽只会使移植物存活率略有增加(m.s.t.,19天)。 TLI联合脾切除术并不比单独使用TLI更有效。 TLI后输注10(7)半同种异体或同种异体骨髓细胞分别在7/8和8/15受体中产生稳定的嵌合体。嵌合体对供体组织具有特殊的耐受性,因为接受C57BL / Ka皮肤移植的时间超过250天,但是第三方(C3H / He)皮肤移植被迅速拒绝了。另外,嵌合淋巴细胞对C3H / He和C3H有反应。 Q但不是单向混合白细胞反应中的C57BL / Ka细胞。 BALB / c C57BL / Ka嵌合体未显示出移植物抗宿主病的临床证据。这些发现可能适用于临床器官移植,因为(a)受体治疗(TLI)已显示对人体安全;(b)捐赠者和接受者可以是完全同种异体的;以及(c)骨髓和皮肤移植生存是永久的(大于250天)。

著录项

  • 作者

  • 作者单位
  • 年度 1977
  • 总页数
  • 原文格式 PDF
  • 正文语种 {"code":"en","name":"English","id":9}
  • 中图分类

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号